RxDoctor Payments Data

Wendy White, MD

Endocrinology, Diabetes & Metabolism · Rancho Mirage, CANPI 1922336114

Payments from drug & device makers

$1,098in general payments, 2019–2025

Across 33 payments — averaging $33.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$378
  • Abbott$210
  • Bayer$121
  • Lilly USA, LLC$68
  • AstraZeneca$45
  • Dexcom, Inc.$45
  • plus $232 from 7 others

What the payments were for

  • Food & beverage$1,07798%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,098 in reported general payments places this provider in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$65,891
Medicare patients
394
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$183,999
JardianceEmpagliflozin68$107,554
MounjaroTirzepatide77$104,161
TrulicityDulaglutide52$74,563
SynjardyEmpagliflozin/Metformin Hcl20$33,938
Tresiba Flextouch U-100Insulin Degludec43$33,638
Tresiba Flextouch U-200Insulin Degludec16$20,623
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$19,561
Fiasp FlextouchInsulin Aspart (Niacinamide)25$18,767
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$10,897
Insulin Lispro Kwikpen U-100Insulin Lispro28$10,255
Lantus SolostarInsulin Glargine,hum.Rec.Anlog71$10,062
SynthroidLevothyroxine Sodium99$9,934
Novolog FlexpenInsulin Aspart15$8,219
Humalog Kwikpen U-100Insulin Lispro20$6,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$68$184,196151 claims
Boehringer IngelheimJardiance, Synjardy$28$141,49288 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →